[{"orgOrder":0,"company":"B. Braun Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Heparin Sodium","moa":"Antithrombin-III","graph1":"Hematology","graph2":"Approved FDF","graph3":"B. Braun Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"B. Braun Medical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"B. Braun Medical \/ Undisclosed"},{"orgOrder":0,"company":"B. Braun Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2017","type":"Inapplicable","leadProduct":"Cefazolin","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"B. Braun Medical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"B. Braun Medical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"B. Braun Medical \/ Undisclosed"},{"orgOrder":0,"company":"B. Braun Medical","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Cefazolin","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"B. Braun Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"B. Braun Medical \/ Parexel","highestDevelopmentStatusID":"6","companyTruncated":"B. Braun Medical \/ Parexel"},{"orgOrder":0,"company":"B. Braun Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Cefazolin","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"B. Braun Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"B. Braun Medical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"B. Braun Medical \/ Undisclosed"},{"orgOrder":0,"company":"B. Braun Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Cefazolin","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"B. Braun Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"B. Braun Medical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"B. Braun Medical \/ Undisclosed"},{"orgOrder":0,"company":"B. Braun Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Cefazolin Sodium","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"B. Braun Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"B. Braun Medical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"B. Braun Medical \/ Undisclosed"},{"orgOrder":0,"company":"B. Braun Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Piperacillin Sodium","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"B. Braun Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"B. Braun Medical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"B. Braun Medical \/ Undisclosed"},{"orgOrder":0,"company":"B. Braun Medical","sponsor":"B. Braun Medical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ITALY","productType":"Amino Acid","year":"2011","type":"Inapplicable","leadProduct":"Betaine","moa":"Betaine-homocysteine S-methyltransferase","graph1":"Dermatology","graph2":"Phase III","graph3":"B. Braun Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"B. Braun Medical \/ B. Braun Medical","highestDevelopmentStatusID":"10","companyTruncated":"B. Braun Medical \/ B. Braun Medical"},{"orgOrder":0,"company":"B. Braun Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Polyhexanide","moa":"Cell membrane","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"B. Braun Medical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Solution","sponsorNew":"B. Braun Medical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"B. Braun Medical \/ Undisclosed"},{"orgOrder":0,"company":"B. Braun Medical","sponsor":"B. Braun Medical","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Aspirin","moa":"Cyclooxygenase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"B. Braun Medical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"B. Braun Medical \/ B. Braun Medical","highestDevelopmentStatusID":"11","companyTruncated":"B. Braun Medical \/ B. Braun Medical"},{"orgOrder":0,"company":"B. Braun Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Dietary Supplement","year":"2010","type":"Inapplicable","leadProduct":"Fish Oil","moa":"Diacylglycerol O-acyltransferase 2; Prostaglandin G\/H synthase 2; Free fatty acid receptor 4; Voltage gated L-type calcium channel; Sodium channel protein; Free radicals; Nuclear factor NF-kappa-B; Sterol regulatory element-binding protein 1; Peroxisome proliferator-activated receptor alpha; Peroxisome proliferator-activated receptor gamma; Peroxisome proliferator-activated receptor delta","graph1":"Undisclosed","graph2":"Phase III","graph3":"B. Braun Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"B. Braun Medical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"B. Braun Medical \/ Undisclosed"},{"orgOrder":0,"company":"B. Braun Medical","sponsor":"Seoul National University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Dual Antiplatelet Therapy","moa":"P2Y12 receptor \/ COX-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"B. Braun Medical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"B. Braun Medical \/ B. Braun Medical","highestDevelopmentStatusID":"11","companyTruncated":"B. Braun Medical \/ B. Braun Medical"},{"orgOrder":0,"company":"B. Braun Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Omega-3-Acid Ethyl Esters 90","moa":"Peroxisome proliferator-activated receptor gamma; Peroxisome proliferator-activated receptor alpha; Sterol regulatory element-binding protein 1","graph1":"Undisclosed","graph2":"Phase III","graph3":"B. Braun Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"B. Braun Medical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"B. Braun Medical \/ Undisclosed"},{"orgOrder":0,"company":"B. Braun Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Carbohydrate","year":"2011","type":"Inapplicable","leadProduct":"Hydroxyethyl Starch","moa":"Plasma volume","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"B. Braun Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"B. Braun Medical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"B. Braun Medical \/ Undisclosed"},{"orgOrder":0,"company":"B. Braun Medical","sponsor":"B. Braun Medical","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Chloroprocaine","moa":"Sodium channel alpha subunit","graph1":"Undisclosed","graph2":"Phase IV","graph3":"B. Braun Medical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"B. Braun Medical \/ B. Braun Medical","highestDevelopmentStatusID":"11","companyTruncated":"B. Braun Medical \/ B. Braun Medical"},{"orgOrder":0,"company":"B. Braun Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Gelaspan","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"B. Braun Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"B. Braun Medical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"B. Braun Medical \/ Undisclosed"},{"orgOrder":0,"company":"B. Braun Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Gelatin","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"B. Braun Medical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"B. Braun Medical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"B. Braun Medical \/ Undisclosed"},{"orgOrder":0,"company":"B. Braun Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Gelofusine","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"B. Braun Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"B. Braun Medical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"B. Braun Medical \/ Undisclosed"},{"orgOrder":0,"company":"B. Braun Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"HES","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"B. Braun Medical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"B. Braun Medical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"B. Braun Medical \/ Undisclosed"},{"orgOrder":0,"company":"B. Braun Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Dietary Supplement","year":"2015","type":"Inapplicable","leadProduct":"Nutricomp Drink Plus","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"B. Braun Medical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"B. Braun Medical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"B. Braun Medical \/ Undisclosed"},{"orgOrder":0,"company":"B. Braun Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Dietary Supplement","year":"2017","type":"Inapplicable","leadProduct":"Nutricomp Drink Plus","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"B. Braun Medical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"B. Braun Medical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"B. Braun Medical \/ Undisclosed"},{"orgOrder":0,"company":"B. Braun Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Nutriflex Lipid Peri","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase III","graph3":"B. Braun Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"B. Braun Medical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"B. Braun Medical \/ Undisclosed"},{"orgOrder":0,"company":"B. Braun Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Omega-6","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"B. Braun Medical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"B. Braun Medical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"B. Braun Medical \/ Undisclosed"},{"orgOrder":0,"company":"B. Braun Medical","sponsor":"Healiva","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Acquisition","leadProduct":"Tissue-engineered Autologous Outer Root Sheath Keratinocyte","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"B. Braun Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"B. Braun Medical \/ Healiva","highestDevelopmentStatusID":"15","companyTruncated":"B. Braun Medical \/ Healiva"},{"orgOrder":0,"company":"B. Braun Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Levetiracetam","moa":"Voltage-gated N-type calcium channel alpha-1B subunit | Synaptic vesicle glycoprotein 2A","graph1":"Neurology","graph2":"Approved FDF","graph3":"B. Braun Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"B. Braun Medical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"B. Braun Medical \/ Undisclosed"},{"orgOrder":0,"company":"B. Braun Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"B. Braun Medical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"B. Braun Medical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"B. Braun Medical \/ Undisclosed"},{"orgOrder":0,"company":"B. Braun Medical","sponsor":"B. Braun Medical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Gelaspan","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"B. Braun Medical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"B. Braun Medical \/ B. Braun Medical","highestDevelopmentStatusID":"11","companyTruncated":"B. Braun Medical \/ B. Braun Medical"}]
Find Clinical Drug Pipeline Developments & Deals by B. Braun Medical
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
